Page 25 - Portuguese Journal - SPORL - Vol 61. Nº2

- Reduction in nasal obstruction Discussion
• Improvement in the symptoms in the VAS: CRS with nasal polyposis is a chronic
reduction ≥ 2 points inflammatory condition with a predominantly
type 2 inflammation profile . It continues
1
Evaluation of the response to treatment: to be an extremely important topic in
4 consultation otorhinolaryngology because of its high
th
- Evaluation of the response at 12 months - prevalence and impact on the patients'
At this stage of treatment, it is necessary that quality of life . Its treatment can be divided
1
all the following criteria are met: into medical and/or surgical. Biologic agents
- Reduction in the size of the polyps have emerged as an important therapeutic
• NPS < 4 (in total, considering both nasal weapon for the control of this disease and
cavities) in nasal endoscopy comorbidities with a type 2 inflammatory
- Improvement in the quality of life component .
22
• Total SNOT-22 score < 30 Based on these assumptions, a working group
- No need for systemic corticosteroids or ESS was set up at Hospital Pedro Hispano that
- Reduction in nasal obstruction included otorhinolaryngology specialists and
• VAS score < 5 interns, with the aim of proposing criteria for
the prescription of biologic agents in patients
with CRS with polyposis, as well as measures
for assessment of cross-sectional efficacy

Table 4
List of adverse reactions

MedDRA Class of organ systems Frequency Adverse reaction
Infections and infestations Frequent Conjunctivitis*
Oral herpes*
Blood and lymphatic system diseases Frequent Eosinophilia
Immune system diseases Not very frequent Angioedema*
Raros Anaphylactic reaction
Serum sickness reaction
Serum sickness-type reaction
Ocular problems Frequent Allergic conjunctivitis*

Not very frequent Keratitis**
Blepharitis*
Eye itching*
Dry eye*

Rare Ulcerative keratitis*
Problems of skin and subcutaneous tissues Not very frequent Facial skin eruption*
Problems of musculoskeletal and Frequent Arthralgia*
connective tissues
General problems and changes in the site Frequent Reactions at the site of injection
of administration (including erithema, edema,
itching, pain, and swelling)

Very frequent (≥ 1/10); frequent (≥ 1/100, < 1/10); not very frequent (≥ 1/1000, < 1/100); rare (≥ 1/10 000, < 1/1000); very rare (< 1/10 000).
Within each group of frequency, the adverse reactions are presented in decreasing order of severity.

Volume 61 . Nº2 . June 2023 167